Shire, AstraZeneca and Hikma hit by Hillary Clinton's pharma-bashing
25th Aug 2016 09:14
(ShareCast News) - Hikma Pharmaceuticals, Shire and AstraZeneca were among FTSE-listed drug companies slipping lower on Thursday morning, following comments from US presidential favourite Hillary Clinton on pharmaceutical pricing that hit peers across the Atlantic overnight. Clinton joined senators
Read moreAstraZeneca sells antibiotics business to Pfizer for £1.2bn
24th Aug 2016 07:11
(ShareCast News) - AstraZeneca has agreed to sell its antibiotics business to US giant Pfizer for staged payments amounting to $1.6bn (£1.2bn) plus recurring, double-digit royalties on future sales. The FTSE 100 group said the sale would reinforces its focus on developing medicines in its three main
Read moreFTSE 100 movers: Housebuilders lead equities higher
23rd Aug 2016 13:58
(ShareCast News) - The FTSE 100 rose 0.66% to 6,873.69 points in afternoon trade on Tuesday, with housebuilders topping the London index. Persimmon led housebuilders higher after reporting a better-than-expected jump in first half profits. Pre-tax profit rose 29% to £352.3m in the six months to 30 J
Read moreAstraZeneca completes licensing agreement with LEO Pharma
16th Aug 2016 07:07
(ShareCast News) - AstraZeneca has completed a licensing agreement with LEO Pharma, a specialist in dermatology care, for the global licence to monoclonal antibody tralokinumab in skin diseases. Upon completion of the agreement, LEO Pharma made a payment to AstraZeneca of $115m for the exclusive, gl
Read moreThursday broker round-up
11th Aug 2016 19:13
(ShareCast News) - Astrazeneca: Berenberg reiterates buy with a target price of 5600p. Legal & General: RBC maintains outperform with a 300p target. Lloyds: JP Morgan reiterates neutral with a 62p target. Centamin: RBC stays at speculative risk with a 190p target. Staffline: Berenberg reiterates
Read moreAstrazeneca ups interest in Moderna Therapeutics with $140m investment
10th Aug 2016 15:17
(ShareCast News) - Astrazeneca has upped its equity interest in Moderna Therapeutics with a $140m investment as part of the biotechnology company's preferred-stock financing. Astrazeneca had already purchased a stake in Massachusetts-based Moderna to develop messenger RNA medicines for the potential
Read moreTuesday broker round-up
9th Aug 2016 12:42
(ShareCast News) - Aviva: Goldman Sachs reiterates buy with a target price of 480p. Antofagasta: RBC maintains sector perform with a 500p target. Informa: Numis reiterates buy with a 845p target. Astrazeneca: JP Morgan stays at neutral with a 4900p target. Topps Tiles: Berenberg reiterates hold w
Read moreAstraZeneca drug fails in lung cancer trial
9th Aug 2016 07:13
(ShareCast News) - Pharmaceutical giant AstraZeneca announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib on Tuesday, in combination with docetaxel chemotherapy, as second-line treatment in patients with KRAS mutation-positive locally-advanced or metastatic non-sm
Read moreThursday broker round-up
4th Aug 2016 11:59
(ShareCast News) - Next: Goldman Sachs reiterates sell with a target price of 4800p. Standard Chartered: JP Morgan maintains overweight with a 800p target. Shire: JP Morgan reiterates overweight with a 6300p target. Genus: HSBC stays at buy with a 2200p target. Nichols: UBS keeps at buy with a ta
Read moreSector movers: Oil-related sectors retreat as Aerospace & Defence flies
28th Jul 2016 16:42
(ShareCast News) - FTSE indices were mixed heading towards the closing bell on Thursday, with the blue-chip index helped south by oil stocks undermined by crude's weakness and Royal Dutch Shell's second-quarter shocker. "An unsurprisingly indecisive session in Europe has seen the likes of the FTSE l
Read moreAstraZeneca earnings see serious fall in first half
28th Jul 2016 08:38
(ShareCast News) - Drug giant AstraZeneca posted its first half results on Thursday, with total revenue down by 3% at constant exchange rates to $11.718bn as expected, reflecting a 2% decline in product sales to $11.034bn.. The FTSE 100 firm said this was driven by patent expiries, in particular Cre
Read moreAstraZeneca celebrates success in latest Tagrisso trial
18th Jul 2016 07:06
(ShareCast News) - AstraZeneca announced on Monday that the Phase III AURA3 trial has met its primary endpoint, demonstrating superior progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy. The FTSE 100 pharmaceutical giant said the AURA3 randomised trial assessed
Read moreAstraZeneca reaches settlement with Sandoz over fulvestrant
13th Jul 2016 07:23
(ShareCast News) - Pharmaceutical giant AstraZeneca announced on Wednesday that it has entered into an agreement with Sandoz and its affiliates to resolve litigation relating to Faslodex (fulvestrant). The FTSE 100 firm said the litigation related to Sandoz's generic fulvestrant product, for which i
Read moreAstraZeneca mulling making a bid for America´s Medivation
11th Jul 2016 08:23
(ShareCast News) - AstraZeneca was mulling joining the fray for US drug outfit Medivation, according to a report published over the weekend. Just at the start of last week the American company, which markets a blockbuster treatment for prostate cancer, saw off another hostile take-over attempt from
Read moreSunday newspaper round-up: AstraZeneca, Asda, Italy
10th Jul 2016 16:58
(ShareCast News) - AstraZeneca is considering tabling a last-minute bid for a $10bn (£7.7bn) American cancer drug developer, which has become a target for some of the world's largest pharmaceutical companies. Medivation, which last week opened its books to Pfizer and Sanofi, is still courting other
Read more